Shopping Cart
- Remove All
Your shopping cart is currently empty
TL13-22
🥰Excellent
Catalog No. T37084Cas No. 2229036-65-9
Alias TL 13-22
TL13-22 is a potent inhibitor of Anaplastic Lymphoma Kinase (ALK) with an IC₅₀ value of 0.54 nM and does not lead to degradation of ALK proteins.TL13-22 is often used as a negative control for TL13-12 (induces ALK protein degradation) as a negative control.TL13-22 also induces degradation of other kinases, including Aurora A, FER, PTK2, and RPS6KA1.
TL13-22
🥰Excellent
Catalog No. T37084Alias TL 13-22Cas No. 2229036-65-9
TL13-22 is a potent inhibitor of Anaplastic Lymphoma Kinase (ALK) with an IC₅₀ value of 0.54 nM and does not lead to degradation of ALK proteins.TL13-22 is often used as a negative control for TL13-12 (induces ALK protein degradation) as a negative control.TL13-22 also induces degradation of other kinases, including Aurora A, FER, PTK2, and RPS6KA1.
| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $329 | In Stock | |
| 5 mg | $826 | In Stock | |
| 10 mg | $1,090 | In Stock | |
| 25 mg | $1,650 | In Stock | |
| 50 mg | $2,230 | In Stock |
Bulk & Custom
Add to Cart
Questions
View MoreInhibitors Related to "TL13-22"
Lorlatinib
Cited
PF-6463922, PF-06463922, Loratinib
T30611454846-35-5
Lorlatinib (PF-6463922) is an orally available, ATP-competitive inhibitor of the receptor tyrosine kinases, anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (Ros1), with potential antineoplastic activity.
- $93
Size
QTY
CitedBrigatinib Cited
AP-26113
T36211197953-54-0
Brigatinib (AP-26113) is a highly potent and selective inhibitor of ALK.
- $30
Size
QTY
CitedVactosertib Cited
TEW-7197, EW-7197
T64961352608-82-2
Vactosertib (EW-7197) is an orally bioavailable inhibitor of the serine/threonine kinase, transforming growth factor (TGF)-beta receptor type 1 (TGFBR1), also known as activin receptor-like kinase 5 (ALK5), with potential antineoplastic activity.
- $39
Size
QTY
CitedA 83-01
Cited
ALK5 Inhibitor IV, A8301
T3031909910-43-6
A 83-01 (ALK5 Inhibitor IV) is an inhibitor of the TGF-β type I receptors ALK5, ALK4, and ALK7 (IC50=12/45/7.5 nM). A 83-01 promotes the reprogramming of mouse fibroblasts into iPSCs. A 83-01 can be used in organoid cultures.
- $52
Size
QTY
CitedCeritinib Cited
LDK378
T17911032900-25-6
Ceritinib (LDK378) is an ALK tyrosine kinase inhibitor (IC50=200 pM) with selective, ATP-competitive, and oral activity. Ceritinib also inhibits IGF-1R, InsR, and STK22D (IC50=8/7/23 nM). Ceritinib has antitumor activity.
- $45
Size
QTY
CitedAlectinib hydrochloride
RO5424802 (Hydrochloride), CH5424802 (Hydrochloride), AF-802 (Hydrochloride)
T83871256589-74-8
Alectinib hydrochloride (RO5424802 Hydrochloride) is a selective, and orally available inhibitor of ALK( IC50 : 1.9 nM)
- $37
Size
QTY
Crizotinib Cited
PF-02341066
T1661877399-52-5
Crizotinib (PF-02341066) is an ATP-competitive small-molecule tyrosine kinase inhibitor of c-MET (IC50: 8 nM) and ALK (IC50: 20 nM) receptors.
- $46
Size
QTY
CitedK02288
K 02288
T19141431985-92-0
K 02288 is a novel small molecule inhibitor of ALK1/2/3/6.
- $33
Size
QTY
Entrectinib Cited
RXDX-101, NMS-E628
T36781108743-60-7
Entrectinib (RXDX-101) is a Trk, ROS1, and ALK inhibitor that inhibits TrkA, TrkB, TrkC, ROS1, and ALK (IC50=1/3/5/12/7 nM) with oral activity and blood-brain-barrier penetration. Entrectinib exhibits both antitumor and CNS activity.
- $35
Size
QTY
CitedAlectinib Cited
RG-7853, CH5424802, AF-802, AF802
T19361256580-46-7
Alectinib (RG-7853) is an ALK inhibitor (IC50=1.9 nM, Kd=2.4 nM) that is selective, orally active, and ATP-competitive. Alectinib has antitumor activity and is used in the treatment of non-small cell lung cancer.
- $39
Size
QTY
CitedSB-431542 Cited
SB 431542
T1726301836-41-9
SB-431542 is an inhibitor of ALK5/TGF-β type I Receptor (IC50=94 nM) and is selective. SB 431542 also has inhibitory activity against ALK4 and ALK7 but not other proteins. SB 431542 can be used for induced differentiation of stem cells.
- $50
Size
QTY
CitedRepSox Cited
SJN 2511, E-616452, ALK5 Inhibitor II
T6337446859-33-2
RepSox (ALK5 Inhibitor II) is a TGFβR-1/ALK5 inhibitor that selectively inhibits the binding of ATP to ALK5 and the autophosphorylation of ALK5 (IC50=23/4 nM). RepSox induces adipogenesis in MEFs cells.
- $30
Size
QTY
CitedContact us for more batch information
Resource Download
Product Introduction
Bioactivity
Chemical Properties
| Description | TL13-22 is a potent inhibitor of Anaplastic Lymphoma Kinase (ALK) with an IC₅₀ value of 0.54 nM and does not lead to degradation of ALK proteins.TL13-22 is often used as a negative control for TL13-12 (induces ALK protein degradation) as a negative control.TL13-22 also induces degradation of other kinases, including Aurora A, FER, PTK2, and RPS6KA1. |
| Targets&IC50 | ALK:0.54 nM |
| In vitro | TL13-22 prompted the concentrations of Aurora A, FER, PTK2 and RPS6KA1 kinase reduction at 11.3, 5.74, 18.4 and 65.9 nM, respectively. [1] |
| Alias | TL 13-22 |
| Molecular Weight | 947.5 |
| Formula | C45H55ClN10O9S |
| Cas No. | 2229036-65-9 |
| Smiles | O=C1C=2C=CC=C(NCC(=O)NCCOCCOCCN3CCN(C4=CC=C(NC5=NC=C(Cl)C(=N5)NC=6C=CC=CC6S(=O)(=O)C(C)C)C(OC)=C4)CC3)C2C(=O)N1C7C(=O)NCCC7 |
Storage & Solubility Information
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 200 mg/mL (211.08 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Calculator
In Vivo Formulation Calculator (Clear solution)
Please enter your animal experiment information in the following box and click Calculate to obtain the mother liquor preparation method and in vivo formula preparation method:
For example, your dosage is 10 mg/kg Each animal weighs 20 g, and the dosage volume is 100 μL . A total of 10 animals were administered, and the formula you used is 5% 
DMSO+30% PEG300+5% Tween 80+60% ddH2O. So your working solution concentration is 2 mg/mL。Mother liquor preparation method: 2 mg of drug dissolved in 50 μL DMSO (mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.
(mother liquor concentration of 40 mg/mL), if you need to configure a concentration that exceeds the solubility of the product, please contact us first.Preparation method for in vivo formula: Take 50 μL DMSO main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarify
main solution, add 300 μLPEG300 mix well and clarify, then add 50 more μL Tween 80, mix well and clarify, then add 600 more μLddH2O mix well and clarifyFor Reference Only. Please develop an appropriate dissolution method based on your laboratory animals and route of administration.
Dose Conversion
You can also refer to dose conversion for different animals. More Dose Conversion
Tech Support
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc
Preview
Related Tags: buy TL13-22 | purchase TL13-22 | TL13-22 cost | order TL13-22 | TL13-22 chemical structure | TL13-22 in vitro | TL13-22 formula | TL13-22 molecular weight
- TOP
Feedback
Hello! How can I help you today? 
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.